
|Articles|June 15, 2004
Topical cyclosporine can handle more than dry-eye disease
Any T-cell-mediated disease benefits from therapy without affecting other inflammatory pathways
Advertisement
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CGTlive®
1
Evaluating Gene Editing Therapy Reni-Cel for Severe Sickle Cell Disease
2
Steven W. Pipe, MD, on the End-of-Study Results From Hemgenix’s HOPE-B Trial
3
Rabi Hanna, MD, on Practical Considerations for Integrating Gene Therapy
4
MDA 2026 to Bring Keynote Insights and Evolving Neuromuscular Care
5
















































